Product Description
Overall, the global artificial heart replacement device market was valued at $11.8 million in 2025. This is expected to increase over the forecast period at a CAGR of 0.21% to reach $12 million.
The full report suite on the global market for artificial heart replacement device includes the mechanical device that replaces the lower chambers of the heart. Once in place, the artificial heart takes over pumping blood throughout your body, restoring healthy circulation. The artificial heart is a temporary solution designed to keep you healthy enough to receive a heart transplant.
Data Types Included
- Unit Sales, Average Selling Prices, Market Size & Growth Trends
- Procedure Numbers
- Market Drivers & Limiters
- Market Forecasts Until 2032, and Historical Data to 2022
- Recent Mergers & Acquisitions
- Company Profiles and Product Portfolios
- Leading Competitors
Artificial Heart Replacement Device Market Trends
As a relatively early-stage segment within the cardiac surgery device market, the artificial heart replacement market is characterized by ongoing research, development, and clinical evaluation. Device manufacturers are actively investing in next-generation designs aimed at improving durability, biocompatibility, and patient quality of life. This trend is expected to continue throughout the forecast period, with multiple devices advancing through clinical trials and regulatory pathways across key global regions.
Artificial Heart Replacement Device Market Share Insights
- SynCardia remains the leading company in the global artificial heart replacement market. Its Total Artificial Heart™ was the first total artificial heart (TAH) to receive U.S. FDA approval and is commercially available in both the United States and Canada. Beyond these markets, the device has been implanted in select cases and clinical studies across more than 27 countries worldwide. While SynCardia is expected to retain a significant share of the global market over the forecast period, its long-standing monopoly is expected to gradually diminish as additional TAH devices from competing manufacturers receive regulatory approval in other regions.
- CARMAT was the second-leading competitor in the artificial heart device market in 2025, supported by its development of the Aeson® total artificial heart. The Aeson system is intended for patients with end-stage biventricular heart failure and is used primarily as a bridge-to-transplant solution rather than a permanent replacement therapy. The device received CE mark approval in Europe and has been implanted in a limited number of patients at selected centers, reflecting a narrow but established commercial presence. Despite its technological differentiation, CARMAT faced ongoing financial and operational challenges and entered court-supervised restructuring in 2025, with its assets and activities transferred to a new entity to allow continued development and limited commercialization. As a result, CARMAT’s market participation remains constrained, with adoption largely confined to early commercial and bridge-to-transplant use cases rather than broad global uptake
Artificial Heart Replacement Device Market Segmentation Summary
- Artificial Heart Replacement Device Market
Research Scope Summary
| Report Attribute | Details |
|---|---|
| Regions | North America (Canada, United States) Latin America (Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Guatemala, Mexico, Panama, Paraguay, Peru, Puerto Rico, Uruguay, Venezuela) Western Europe (Austria, Benelux, France, Germany, Italy, Portugal, Scandinavia, Spain, Switzerland, United Kingdom) Central & Eastern Europe (Azerbaijan, Baltic States, Belarus, Bulgaria, Croatia, Czech Republic, Georgia, Greece, Hungary, Kazakhstan, Poland, Romania, Russia, Serbia, Slovakia, Slovenia, Turkey, Ukraine) Middle East (Bahrain, Iran, Israel, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates) Asia Pacific (Australia, Cambodia, China, Hong Kong, India, Indonesia, Japan, Kyrgyzstan, Macao, Malaysia, Mongolia, Myanmar, New Zealand, Pakistan, Philippines, Singapore, South Korea, Sri Lanka, Taiwan, Thailand, Uzbekistan, Vietnam) Africa (Algeria, Egypt, Ethiopia, Ghana, Kenya, Libya, Morocco, Nigeria, South Africa, Sudan, Uganda) |
| Base Year | 2025 |
| Forecast | 2026-2032 |
| Historical Data | 2022-2024 |
| Quantitative Coverage | Market Size, Market Shares, Market Forecasts, Market Growth Rates, Units Sold, and Average Selling Prices. |
| Qualitative Coverage | Market Growth Trends, Market Limiters, Competitive Analysis & SWOT for Top Competitors, Mergers & Acquisitions, Company Profiles, Product Portfolios, FDA Recalls, Disruptive Technologies, Disease Overviews. |
| Data Sources | Primary Interviews with Industry Leaders, Government Physician Data, Regulatory Data, Hospital Private Data, Import & Export Data, iData Research Internal Database. |
CONTACT US FOR ADDITIONAL INFORMATION
For full segmentation and any questions regarding research coverage, please contact us for a complimentary demo of the full report.
